Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | DPP4 | P27487 | 2/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MIF | P14174 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7781865 | 1.00 | TAAR1 (0.39) | TAAR1CYP3A4TDP1KDM4EADRA2A | |
| SCHEMBL6288575 | 0.80 | TAAR1 (0.40) | TAAR1CYP3A4TDP1KDM4EADRA2A | |
| SCHEMBL8467150 | 0.80 | CYP3A4 (0.39) | TAAR1CYP3A4TDP1LMNAHIF1A | |
| SCHEMBL28980077 | 0.76 | HTR2A (0.49) | ALDH1A1 | |
| SCHEMBL18219540 | 0.76 | TAAR1 (0.39) | TAAR1CYP3A4TDP1KDM4EADRA2A | |
| SCHEMBL4369978 | 0.76 | TAAR1 (0.37) | TAAR1CYP3A4TDP1KDM4EADRA2A | |
| SCHEMBL12584889 | 0.76 | TDP1 (0.45) | TAAR1CYP3A4TDP1KDM4EADRA2A | |
| SCHEMBL104024 | 0.76 | TDP1 (0.45) | TAAR1CYP3A4TDP1KDM4EADRA2A | |
| SCHEMBL29178 | 0.76 | TDP1 (0.45) | TAAR1CYP3A4TDP1KDM4EADRA2A | |
| SCHEMBL18832827 | 0.76 | TDP1 (0.45) | TAAR1CYP3A4TDP1KDM4EADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020137820-A1 | Phosphorus compounds | SANDOZ LTD. (CH) | 2002-09-26 | — | — | US | claimed |
| US-10103401-B2 | Polymer electrolyte composition and polymer electrolyte membrane, polymer electrolyte membrane with catalyst layer, membrane electrode assembly, and polymer electrolyte fuel cell each using the same | TORAY INDUSTRIES, INC. (JP) | 2018-10-16 | — | — | US | disclosed |
| EP-3131145-B1 | POLYMER ELECTROLYTE COMPOSITION AND POLYMER ELECTROLYTE MEMBRANE, MEMBRANE-ELECTROLYTE ASSEMBLY, AND SOLID POLYMER FUEL CELL USING SAME | TORAY INDUSTRIES (JP) | 2018-09-05 | — | — | EP | disclosed |
| US-20170125832-A1 | POLYMER ELECTROLYTE COMPOSITION AND POLYMER ELECTROLYTE MEMBRANE, POLYMER ELECTROLYTE MEMBRANE WITH CATALYST LAYER, MEMBRANE ELECTRODE ASSEMBLY, AND POLYMER ELECTROLYTE FUEL CELL EACH USING THE SAME | TORAY INDUSTRIES, INC. (JP) | 2017-05-04 | — | — | US | disclosed |
| EP-3131145-A1 | POLYMER ELECTROLYTE COMPOSITION AND POLYMER ELECTROLYTE MEMBRANE, MEMBRANE-ELECTROLYTE ASSEMBLY, AND SOLID POLYMER FUEL CELL USING SAME | Toray Industries, Inc. (JP) | 2017-02-15 | — | — | EP | disclosed |
| CN-105153009-A | Bimaleimide with asymmetric molecular structure and preparation methods thereof, and application of bimaleimide in preparation of composite resin | UNIV FUDAN | 2015-12-16 | — | — | CN | disclosed |
| US-7465838-B2 | Chiral diols, their manufacture and ligands and catalysts derived therefrom | CIBA SPECIALTY CHEMICAL CORP. (US) | 2008-12-16 | — | — | US | disclosed |
| US-20060030737-A1 | Chiral diols, their manufacture and ligands and catalysts derived therefrom | CIBA SPECIALTY CHEMICALS CORP. | 2006-02-09 | — | — | US | disclosed |
| EP-1582527-A1 | Synthesis of phosphorus based ligands | Ciba SC Holding AG (CH) | 2005-10-05 | — | — | EP | disclosed |
| CN-1675333-A | Compounds comprising phosphorus-containing metal complexes | DU PONT (US) | 2005-09-28 | — | — | CN | disclosed |
| EP-0989122-A1 | Process for the preparation of imidazolidine-2,4-diones | Degussa-Hüls Aktiengesellschaft (DE) | 2000-03-29 | — | — | EP | disclosed |
| US-5488079-A | HEAT AND LIGHT STABILIZERS FOR OLEFINS USING PHOSPHINES | SANDOZ LTD. (CH) | 1996-01-30 | — | — | US | disclosed |
| US-4687874-A | Selective hydroformylation process using alkyl diaryl phosphine rhodium carbonyl hydride catalysts | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1987-08-18 | — | — | US | disclosed |
| US-4687866-A | Ligand exchange process for producing alkyl diaryl phosphine rhodium carbonyl hydrides | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1987-08-18 | — | — | US | disclosed |
| US-4668809-A | ALKYL DIARYLPHOSPHINE RHODIUM CARBONYL HYDRIDES, HYDROFORMYLATION, OLEFINS | EXXON RESEARCH AND ENGINEERING (US) | 1987-05-26 | — | — | US | disclosed |
| US-4595753-A | Nitrogen heterocycle substituted | EXXON RESEARCH AND ENGINEERING CO. (US) | 1986-06-17 | — | — | US | disclosed |
| EP-0024091-B1 | HYDROFORMYLATION PROCESS AND NOVEL TRANSITION METAL CATALYSTS | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1985-04-03 | — | — | EP | disclosed |
| EP-0024091-A4 | HYDROFORMYLATION PROCESS AND NOVEL TRANSITION METAL CATALYSTS. | EXXON RESEARCH ENGINEERING CO (US) | 1981-07-16 | — | — | EP | disclosed |
| EP-0024091-A1 | HYDROFORMYLATION PROCESS AND NOVEL TRANSITION METAL CATALYSTS. | EXXON RESEARCH ENGINEERING CO (US) | 1981-02-25 | — | — | EP | disclosed |
| WO-1980001690-A1 | CARBONYLATION PROCESS AND NOVEL TRANSITION METAL CATALYSTS | EXXON RESEARCH ENGINEERING CO (US) | 1980-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030737-A1 | Chiral diols, their manufacture and ligands and catalysts derived therefrom | B2M, CYP4F11, CYP2F1 | TAAR1 1331/4885CYP3A4 84/4885TDP1 4145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.